1
|
Yang B, Xu S, Wang D, Chen Y, Zhou Z, Shen C. ACEI/ARB Medication During ICU Stay Decrease All-Cause In-hospital Mortality in Critically Ill Patients With Hypertension: A Retrospective Cohort Study Based on Machine Learning. Front Cardiovasc Med 2022; 8:787740. [PMID: 35097006 PMCID: PMC8791359 DOI: 10.3389/fcvm.2021.787740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Accepted: 12/07/2021] [Indexed: 01/08/2023] Open
Abstract
Background: Hypertension is a rather common comorbidity among critically ill patients and hospital mortality might be higher among critically ill patients with hypertension (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg). This study aimed to explore the association between ACEI/ARB medication during ICU stay and all-cause in-hospital mortality in these patients. Methods: A retrospective cohort study was conducted based on data from Medical Information Mart for Intensive Care IV (MIMIC-IV) database, which consisted of more than 40,000 patients in ICU between 2008 and 2019 at Beth Israel Deaconess Medical Center. Adults diagnosed with hypertension on admission and those had high blood pressure (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg) during ICU stay were included. The primary outcome was all-cause in-hospital mortality. Patients were divided into ACEI/ARB treated and non-treated group during ICU stay. Propensity score matching (PSM) was used to adjust potential confounders. Nine machine learning models were developed and validated based on 37 clinical and laboratory features of all patients. The model with the best performance was selected based on area under the receiver operating characteristic curve (AUC) followed by 5-fold cross-validation. After hyperparameter optimization using Grid and random hyperparameter search, a final LightGBM model was developed, and Shapley Additive exPlanations (SHAP) values were calculated to evaluate feature importance of each feature. The features closely associated with hospital mortality were presented as significant features. Results: A total of 15,352 patients were enrolled in this study, among whom 5,193 (33.8%) patients were treated with ACEI/ARB. A significantly lower all-cause in-hospital mortality was observed among patients treated with ACEI/ARB (3.9 vs. 12.7%) as well as a lower 28-day mortality (3.6 vs. 12.2%). The outcome remained consistent after propensity score matching. Among nine machine learning models, the LightGBM model had the highest AUC = 0.9935. The SHAP plot was employed to make the model interpretable based on LightGBM model after hyperparameter optimization, showing that ACEI/ARB use was among the top five significant features, which were associated with hospital mortality. Conclusions: The use of ACEI/ARB in critically ill patients with hypertension during ICU stay is related to lower all-cause in-hospital mortality, which was independently associated with increased survival in a large and heterogeneous cohort of critically ill hypertensive patients with or without kidney dysfunction.
Collapse
Affiliation(s)
- Boshen Yang
- Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
| | - Sixuan Xu
- Intelligent Transportation Systems Research Center, School of Transportation, Southeast University, Nanjing, China
| | - Di Wang
- Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
| | - Yu Chen
- Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
| | - Zhenfa Zhou
- Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
| | - Chengxing Shen
- Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
- *Correspondence: Chengxing Shen
| |
Collapse
|
2
|
van Hespen KM, Mackaaij C, Waas ISE, de Bree MP, Zwanenburg JJM, Kuijf HJ, Daemen MJAP, Hendrikse J, Hermkens DMA. Arterial Remodeling of the Intracranial Arteries in Patients With Hypertension and Controls: A Postmortem Study. Hypertension 2020; 77:135-146. [PMID: 33222546 DOI: 10.1161/hypertensionaha.120.16029] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The intracranial arteries play a major role in cerebrovascular disease, but arterial remodeling due to hypertension has not been well described in humans. We aimed to quantify this remodeling for: the basilar artery, the vertebral, internal carotid, middle/anterior (inferior)/posterior cerebral, posterior communicating, and superior cerebellar arteries of the circle of Willis. Ex vivo circle of Willis specimens, selected from individuals with (n=24) and without (n=25) a history of hypertension, were imaged at 7T magnetic resonance imaging using a 3-dimensional gradient-echo sequence. Subsequently, histological analysis was performed. We validated the vessel wall thickness and area measurements from magnetic resonance imaging against histology. Next, we investigated potential differences in vessel wall thickness and area between both groups using both techniques. Finally, using histological analysis, we investigated potential differences in arterial wall stiffness and atherosclerotic plaque severity and load. All analyses were unadjusted. Magnetic resonance imaging and histology showed comparable vessel wall thickness (mean difference: 0.04 mm (limits of agreement:-0.12 to 0.19 mm) and area (0.43 mm2 [-0.97 to 1.8 mm2]) measurements. We observed no statistically significant differences in vessel wall thickness and area between both groups using either technique. Histological analysis showed early and advanced atherosclerotic plaques in almost all arteries for both groups. The arterial wall stiffness was significantly higher for the internal carotid artery in the hypertensive group. Concluding, we did not observe vessel wall thickening in the circle of Willis arteries in individuals with a history of hypertension using either technique. Using histological analysis, we observed a difference in vessel wall composition for the internal carotid artery.
Collapse
Affiliation(s)
- Kees M van Hespen
- From the Center for Image Sciences (K.M.v.H.), University Medical Center Utrecht, the Netherlands
| | - Claire Mackaaij
- Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands (C.M., I.S.E.W., M.P.D.B., M.J.A.P.D., D.M.A.H.)
| | - Ingeborg S E Waas
- Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands (C.M., I.S.E.W., M.P.D.B., M.J.A.P.D., D.M.A.H.)
| | - Marloes P de Bree
- Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands (C.M., I.S.E.W., M.P.D.B., M.J.A.P.D., D.M.A.H.)
| | - Jaco J M Zwanenburg
- Department of Radiology (J.J.M.Z., J.H.), University Medical Center Utrecht, the Netherlands
| | - Hugo J Kuijf
- Image Sciences Institute (H.J.K.), University Medical Center Utrecht, the Netherlands
| | - Mat J A P Daemen
- Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands (C.M., I.S.E.W., M.P.D.B., M.J.A.P.D., D.M.A.H.)
| | - Jeroen Hendrikse
- Department of Radiology (J.J.M.Z., J.H.), University Medical Center Utrecht, the Netherlands
| | - Dorien M A Hermkens
- Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands (C.M., I.S.E.W., M.P.D.B., M.J.A.P.D., D.M.A.H.)
| |
Collapse
|
3
|
Markan U, Pasupuleti S, Pollard CM, Perez A, Aukszi B, Lymperopoulos A. The place of ARBs in heart failure therapy: is aldosterone suppression the key? Ther Adv Cardiovasc Dis 2019; 13:1753944719868134. [PMID: 31401939 PMCID: PMC6691655 DOI: 10.1177/1753944719868134] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Since the launch of the first orally available angiotensin II (AngII) type 1 receptor (AT1R) blocker (ARB) losartan (Cozaar) in the late 1990s, the class of ARBs (or ‘sartans’, short for Angiotensin-RecepTor-ANtagonistS) quickly expanded to include candesartan, eprosartan, irbesartan, valsartan, telmisartan, and olmesartan. All ARBs have high affinity for the AT1 receptor, expressed in various tissues, including smooth muscle cells, heart, kidney, and brain. Since activation of AT1R, the target of these drugs, leads, among other effects, to vascular smooth muscle cell growth, proliferation and contraction, activation of fibroblasts, cardiac hypertrophy, aldosterone secretion from the adrenal cortex, thirst-fluid intake (hypervolemia), etc., the ARBs are nowadays one of the most useful cardiovascular drug classes used in clinical practice. However, significant differences in their pharmacological and clinical properties exist that may favor use of particular agents over others within the class, and, in fact, two of these drugs, candesartan and valsartan, continuously appear to distinguish themselves from the rest of the ‘pack’ in recent clinical trials. The reason(s) for the potential superiority of these two agents within the ARB class are currently unclear but under intense investigation. The present short review gives an overview of the clinical properties of the ARBs currently approved by the United States Food and Drug Administration, with a particular focus on candesartan and valsartan and the areas where these two drugs seem to have a therapeutic edge. In the second part of our review, we outline recent data from our laboratory (mainly) on the molecular effects of the ARB drugs on aldosterone production and on circulating aldosterone levels, which may underlie (at least in part) the apparent clinical superiority of candesartan (and valsartan) over most other ARBs currently in clinical use.
Collapse
Affiliation(s)
- Uma Markan
- Laboratory for the Study of Neurohormonal Control of the Circulation, Department of Pharmaceutical Sciences, Nova Southeastern University College of Pharmacy, Fort Lauderdale, FL, USA
| | - Samhitha Pasupuleti
- Laboratory for the Study of Neurohormonal Control of the Circulation, Department of Pharmaceutical Sciences, Nova Southeastern University College of Pharmacy, Fort Lauderdale, FL, USA
| | - Celina M Pollard
- Laboratory for the Study of Neurohormonal Control of the Circulation, Department of Pharmaceutical Sciences, Nova Southeastern University College of Pharmacy, Fort Lauderdale, FL, USA
| | - Arianna Perez
- Laboratory for the Study of Neurohormonal Control of the Circulation, Department of Pharmaceutical Sciences, Nova Southeastern University College of Pharmacy, Fort Lauderdale, FL, USA
| | - Beatrix Aukszi
- Department of Chemistry and Physics, Halmos College of Natural Sciences and Oceanography, Nova Southeastern University, Fort Lauderdale, FL, USA
| | - Anastasios Lymperopoulos
- Department of Pharmaceutical Sciences, Nova Southeastern University College of Pharmacy, 3200 S. University Dr., HPD (Terry) Bldg/Room 1338, Fort Lauderdale, FL 33328-2018, USA
| |
Collapse
|
4
|
Ferrario CM, Mullick AE. Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacol Res 2017; 125:57-71. [PMID: 28571891 PMCID: PMC5648016 DOI: 10.1016/j.phrs.2017.05.020] [Citation(s) in RCA: 77] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/17/2017] [Revised: 05/11/2017] [Accepted: 05/15/2017] [Indexed: 02/07/2023]
Abstract
A collective century of discoveries establishes the importance of the renin angiotensin aldosterone system in maintaining blood pressure, fluid volume and electrolyte homeostasis via autocrine, paracrine and endocrine signaling. While research continues to yield new functions of angiotensin II and angiotensin-(1-7), the gap between basic research and clinical application of these new findings is widening. As data accumulates on the efficacy of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers as drugs of fundamental importance in the treatment of cardiovascular and renal disorders, it is becoming apparent that the achieved clinical benefits is suboptimal and surprisingly no different than what can be achieved with other therapeutic interventions. We discuss this issue and summarize new pathways and mechanisms effecting the synthesis and actions of angiotensin II. The presence of renin-independent non-canonical pathways for angiotensin II production are largely unaffected by agents inhibiting renin angiotensin system activity. Hence, new efforts should be directed to develop drugs that can effectively block the synthesis and/or action of intracellular angiotensin II. Improved drug penetration into cardiac or renal sites of disease, inhibiting chymase the primary angiotensin II forming enzyme in the human heart, and/or inhibiting angiotensinogen synthesis would all be more effective strategies to inhibit the system. Additionally, given the role of angiotensin II in the maintenance of renal homeostatic mechanisms, any new inhibitor should possess greater selectivity of targeting pathogenic angiotensin II signaling processes and thereby limit inappropriate inhibition.
Collapse
Affiliation(s)
- Carlos M Ferrario
- Department of Surgery, Wake Forest University Health Science, Medical Center Blvd., Winston Salem, NC 27157, United States.
| | - Adam E Mullick
- Cardiovascular Antisense Drug Discovery, Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, United States
| |
Collapse
|
5
|
Abstract
Successful treatment of hypertension is possible with limited side effects given the availability of multiple antihypertensive drug classes. This review describes the various pharmacological classes of antihypertensive drugs, under two major aspects: their mechanisms of action and side effects. The mechanism of action is analysed through a pharmacological approach, i.e. the molecular receptor targets, the various sites along the arterial system, and the extra-arterial sites of action, in order to better understand in which type of hypertension a given pharmacological class of antihypertensive drug is most indicated. In addition, side effects are described and explained through their pharmacological mechanisms, in order to better understand their mechanism of occurrence and in which patients drugs are contra-indicated. This review does not address the effectiveness of monotherapies in large randomized clinical trials and combination therapies, since these are the matters of other articles of the present issue. Five major pharmacological classes of antihypertensive drugs are detailed here: beta-blockers, diuretics, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium channel blockers. Four additional pharmacological classes are described in a shorter manner: renin inhibitors, alpha-adrenergic receptor blockers, centrally acting agents, and direct acting vasodilators.
Collapse
Affiliation(s)
- Stéphane Laurent
- Department of Pharmacology and INSERM U 970, Hôpital Européen Georges Pompidou, Paris-Descartes University, Assistance Publique - Hôpitaux de Paris, 56 rue Leblanc, 75015, Paris, France.
| |
Collapse
|
6
|
Rochlani Y, Khan MH, Banach M, Aronow WS. Are two drugs better than one? A review of combination therapies for hypertension. Expert Opin Pharmacother 2017; 18:377-386. [PMID: 28129695 DOI: 10.1080/14656566.2017.1288719] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Yogita Rochlani
- Cardiology Division, Department of Medicine, New York Medical College, Valhalla, NY, USA
| | - Mohammed Hasan Khan
- Cardiology Division, Department of Medicine, New York Medical College, Valhalla, NY, USA
| | - Maciej Banach
- Department of Hypertension, Divisions of Nephrology and Hypertension, MUL, Lodz, Poland
| | - Wilbert S. Aronow
- Cardiology Division, Department of Medicine, New York Medical College, Valhalla, NY, USA
| |
Collapse
|
7
|
Agrawal V, Gupta JK, Qureshi SS, Vishwakarma VK. Role of cardiac renin angiotensin system in ischemia reperfusion injury and preconditioning of heart. Indian Heart J 2016; 68:856-861. [PMID: 27931559 PMCID: PMC5143827 DOI: 10.1016/j.ihj.2016.06.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Revised: 06/14/2016] [Accepted: 06/21/2016] [Indexed: 12/25/2022] Open
Abstract
Cardio-vascular diseases are the leading cause of morbidity and mortality. Ischemia is a state of oxygen deprivation in tissues, whereas reperfusion is restoration of blood flow in ischemic tissues. Myocardial damage of tissue during reperfusion after ischemic insult is known as myocardial ischemia–reperfusion (I/R) injury. It induces damage to cardiac muscle via increasing expression of oxygen, sodium and calcium ions which are responsible in the activation of proteases and cell death. Heart renin angiotensin system (RAS) plays an important role in the myocardial ischemia and reperfusion injury. Angiotensin (1–7) is responsible for vasodilation and angiotensin II for vasoconstriction. Here-in we reviewed how myocardial I/R injury sets in by up-regulation of angiotensin II that leads to increased infarct size, which can be reduced by the use of ACE inhibitors, ACE2 activators and angiotensin II antagonist.
Collapse
Affiliation(s)
- Vimal Agrawal
- Institute of Pharmaceutical Research, GLA University, Mathura, UP, India
| | | | | | | |
Collapse
|
8
|
Bertorello AM, Pires N, Igreja B, Pinho MJ, Vorkapic E, Wågsäter D, Wikström J, Behrendt M, Hamsten A, Eriksson P, Soares-da-Silva P, Brion L. Increased Arterial Blood Pressure and Vascular Remodeling in Mice Lacking Salt-Inducible Kinase 1 (SIK1). Circ Res 2015; 116:642-52. [DOI: 10.1161/circresaha.116.304529] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Rationale:
In human genetic studies a single nucleotide polymorphism within the salt-inducible kinase 1 (
SIK1
) gene was associated with hypertension. Lower SIK1 activity in vascular smooth muscle cells (VSMCs) leads to decreased sodium-potassium ATPase activity, which associates with increased vascular tone. Also, SIK1 participates in a negative feedback mechanism on the transforming growth factor-β1 signaling and downregulation of SIK1 induces the expression of extracellular matrix remodeling genes.
Objective:
To evaluate whether reduced expression/activity of SIK1 alone or in combination with elevated salt intake could modify the structure and function of the vasculature, leading to higher blood pressure.
Methods and Results:
SIK1 knockout (
sik1
−/−
) and wild-type (
sik1
+/+
) mice were challenged to a normal- or chronic high-salt intake (1% NaCl). Under normal-salt conditions, the
sik1
−/−
mice showed increased collagen deposition in the aorta but similar blood pressure compared with the
sik1
+/+
mice. During high-salt intake, the
sik1
+/+
mice exhibited an increase in SIK1 expression in the VSMCs layer of the aorta, whereas the
sik1
−/−
mice exhibited upregulated transforming growth factor-β1 signaling and increased expression of endothelin-1 and genes involved in VSMC contraction, higher systolic blood pressure, and signs of cardiac hypertrophy. In vitro knockdown of SIK1 induced upregulation of collagen in aortic adventitial fibroblasts and enhanced the expression of contractile markers and of endothelin-1 in VSMCs.
Conclusions:
Vascular SIK1 activation might represent a novel mechanism involved in the prevention of high blood pressure development triggered by high-salt intake through the modulation of the contractile phenotype of VSMCs via transforming growth factor-β1-signaling inhibition.
Collapse
Affiliation(s)
- Alejandro M. Bertorello
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Nuno Pires
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Bruno Igreja
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Maria João Pinho
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Emina Vorkapic
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Dick Wågsäter
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Johannes Wikström
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Margareta Behrendt
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Anders Hamsten
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Per Eriksson
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Patricio Soares-da-Silva
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Laura Brion
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| |
Collapse
|
9
|
Gu J, Wang JJ, Yan J, Cui CF, Wu WH, Li L, Wang ZS, Yu M, Gao N, Liu L, Ouyang DS. Effects of lignans extracted from Eucommia ulmoides and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling. JOURNAL OF ETHNOPHARMACOLOGY 2011; 133:6-13. [PMID: 20817083 DOI: 10.1016/j.jep.2010.08.055] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2010] [Revised: 08/23/2010] [Accepted: 08/26/2010] [Indexed: 05/04/2023]
Abstract
AIM OF THE STUDY To investigate the effects of lignans extracted from Eucommia ulmoides and epalrestat on vascular remodeling in spontaneously hypertensive rats. MATERIALS AND METHODS Ten-week-old male spontaneously hypertensive rats were randomly divided into 3 groups (12 rats each group), and treated orally with 100 mg/kg/d of captopril (an angiotensin-converting enzyme inhibitor), 100 mg/kg/d of epalrestat (an aldose reductase inhibitor) and 300 mg/kg/d of lignans by gavage daily for 16 weeks, respectively. Sex-, age-, and number-matched spontaneously hypertensive rats and normotensive Wistar Kyoto rats, were treated with distilled water (vehicle) as controls. The rats were weighed weekly. Mean arterial blood pressure and heart rate were measured periodically by non-invasive blood pressure monitoring. They were sacrificed at the end of experiment (26-week-old). Superior mesenteric artery and aorta were isolated for determination of histomorphometry and the expression of aldose reductase by immunohistochemistry. RESULTS Captopril and lignans, but not epalrestat, decreased mean arterial blood pressure in spontaneously hypertensive rats. Vascular remodeling was improved in all three treated groups by histomorphometry. CONCLUSIONS Both lignans and epalrestat reversed hypertensive vascular remodeling. Aldose reductase played a vital role in the pathologic process of hypertensive vascular remodeling rather than elevation of blood pressure. These data suggested that aldose reductase could be a new therapeutic target for the treatment of cardiovascular diseases.
Collapse
Affiliation(s)
- Juan Gu
- Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, PR China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Lim SM, Kreipe BA, Trzeciakowski J, Dangott L, Trache A. Extracellular matrix effect on RhoA signaling modulation in vascular smooth muscle cells. Exp Cell Res 2010; 316:2833-48. [PMID: 20599954 DOI: 10.1016/j.yexcr.2010.06.010] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2010] [Revised: 05/25/2010] [Accepted: 06/09/2010] [Indexed: 02/02/2023]
Abstract
Morphological adaptations of vascular smooth muscle cells (VSMC) to the mechanically active environment in which they reside, are mediated by direct interactions with the extracellular matrix (ECM) which induces physiological changes at the intracellular level. This study aimed to analyze the effects of the ECM on RhoA-induced mechanical signaling that controls actin organization and focal adhesion formation. VSMC were transfected with RhoA constructs (wild type, dominant negative or constitutively active) and plated on different ECM proteins used as substrate (fibronectin, collagen IV, collagen I, and laminin) or poly-l-lysine as control. Morphological changes of the VSMC were detected by fluorescence confocal microscopy and total internal reflection fluorescence (TIRF) microscopy, and were independently verified using adhesion assays and Western blot analysis. Our results showed that the ECM has an important role in cell spreading, adhesion and morphology with a direct effect on modulating RhoA signaling. RhoA activity significantly affected the stress fibers and focal adhesions reorganization, but in a context imposed by the ECM. Thus, RhoA activity modulation in VSMC induced an increased activation of stress fibers and FA formation at 5h, while a significant inhibition was recorded at 24h after plating on the different ECM. Our findings provide biophysical evidence that ECM modulates VSMC response to mechanical stimuli inducing intracellular biochemical signaling involved in cellular adaptation to the local microenvironment.
Collapse
Affiliation(s)
- Soon-Mi Lim
- Department of Systems Biology & Translational Medicine, College of Medicine, Cardiovascular Research Institute, Texas A&M Health Science Center, 336 Reynolds Medical Bldg., College Station, TX 77843-1114, USA
| | | | | | | | | |
Collapse
|
11
|
|
12
|
Sica DA. The Evolution of Renin-Angiotensin Blockade: Angiotensin-Converting Enzyme Inhibitors as the Starting Point. Curr Hypertens Rep 2010; 12:67-73. [DOI: 10.1007/s11906-010-0091-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
13
|
Schiffrin EL. Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature. J Cell Mol Med 2010; 14:1018-29. [PMID: 20345850 PMCID: PMC3822736 DOI: 10.1111/j.1582-4934.2010.01056.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
This review addresses the use of the different antihypertensive agents currently available and some in development, and their effects on the vasculature. The different classes of agents used in the treatment of hypertension, and the results of recent large clinical trials, dosing protocols and adverse effects are first briefly summarized. The consequences on blood vessels of the use of antihypertensive drugs and the differential effects on the biology of large and small arteries resulting in modulation of vascular remodelling and dysfunction in hypertensive patients are then described. Large elastic conduit arteries exhibit outward hypertrophic remodelling and increased stiffness, which contributes to raise systolic blood pressure and afterload on the heart. Small resistance arteries undergo eutrophic or hypertrophic inward remodelling, and impair tissue perfusion. By these mechanisms both large and small arteries may contribute to trigger cardiovascular events. Some antihypertensive agents correct these changes, which could contribute to improved outcome. The mechanisms that at the level of the vascular wall lead to remodelling and can be beneficially affected by antihypertensive agents will also be addressed. These include vasoconstriction, growth and inflammation. The molecular pathways contributing to growth and inflammation will be summarily described. Further identification of these signalling pathways should allow identification of novel targets leading to development of new and improved medications for the treatment of hypertension and cardiovascular disease.
Collapse
Affiliation(s)
- Ernesto L Schiffrin
- Department of Medicine, Sir Mortimer B Davis Jewish General Hospital, Montreal, Québec, Canada.
| |
Collapse
|
14
|
Martinez-Lemus LA, Hill MA, Meininger GA. The plastic nature of the vascular wall: a continuum of remodeling events contributing to control of arteriolar diameter and structure. Physiology (Bethesda) 2009; 24:45-57. [PMID: 19196651 DOI: 10.1152/physiol.00029.2008] [Citation(s) in RCA: 162] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The diameter of resistance arteries has a profound effect on the distribution of microvascular blood flow and the control of systemic blood pressure. Here, we review mechanisms that contribute to the regulation of resistance artery diameter, both acutely and chronically, their temporal characteristics, and their interdependence. Furthermore, we hypothesize the existence of a remodeling continuum that allows for the vascular wall to rapidly modify its structural characteristics, specifically through the re-positioning of vascular smooth muscle cells. Importantly, the concepts presented more closely link acute vasoregulatory responses with adaptive changes in vessel wall structure. These rapid structural adaptations provide resistance vessels the ability to maintain a desired diameter under presumed optimal energetic and mechanical conditions.
Collapse
Affiliation(s)
- Luis A Martinez-Lemus
- Dalton Cardiovascular Research Center and Department of Medical Pharmacology and Physiology, University of Missouri-Columbia, Columbia, Missouri, USA
| | | | | |
Collapse
|
15
|
Effects of hyperglycemia on the modulation of vascular function by perivascular adipose tissue. J Hypertens 2009; 27:118-31. [PMID: 19050452 DOI: 10.1097/hjh.0b013e3283163cc9] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVE To study the acute and chronic effect of hyperglycemia on perivascular adipose tissue (PVAT) function in rat aorta. METHOD Alterations in PVAT function in rat aorta incubated with 22 mmol/l D-glucose for 30 min and in aorta from streptozotocin (STZ)-induced diabetic rats were studied. RESULTS Incubation with D-glucose caused an attenuation of contraction in response to phenylephrine, both in the presence and absence of endothelium, whereas removal of PVAT eliminated this attenuation effect. The presence of PVAT did not affect concentration-related relaxation response of the aorta to carbamylcholine in STZ rats. There was also no difference in the relaxation response of the aorta to carbamylcholine between STZ and control rats. The presence of PVAT, however, caused a higher attenuation of the concentration-dependent contraction to phenylephrine in aorta from STZ rats with intact endothelium as compared with that from control rats. Incubation of the aorta from control rats with Nomega-nitro-L-arginine or carboxy-2-phenyl-4,4,5,5-tetra-methyl-imidazoline-1-oxyl-3-oxide potentiated the contraction of the vessels to phenylephrine, and this potentiation effect was higher in the vessels from STZ rats than control rats when N-nitro-L-arginine was used. Removal of PVAT reduced this potentiation effect and eliminated the difference between the vessels from control and STZ rats. CONCLUSION Under both acute and chronic conditions, hyperglycemia enhanced the relaxation response of the vessels mediated by PVAT. These new findings provide important information on the mechanism underlying the postprandial effect of hyperglycemia on blood pressure control and the presence of hypotension under chronic hyperglycemia in a type-1 model of diabetes.
Collapse
|
16
|
Gratze P, Dechend R, Stocker C, Park JK, Feldt S, Shagdarsuren E, Wellner M, Gueler F, Rong S, Gross V, Obst M, Plehm R, Alenina N, Zenclussen A, Titze J, Small K, Yokota Y, Zenke M, Luft FC, Muller DN. Novel role for inhibitor of differentiation 2 in the genesis of angiotensin II-induced hypertension. Circulation 2008; 117:2645-56. [PMID: 18474814 DOI: 10.1161/circulationaha.107.760116] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Angiotensin (Ang) II-induced target-organ damage involves innate and acquired immunity. Mice deficient for the helix-loop-helix transcription factor inhibitor of differentiation (Id2(-/-)) lack Langerhans and splenic CD8a+ dendritic cells, have reduced natural killer cells, and have altered CD8 T-cell memory. We tested the hypothesis that an alteration in the number and quality of circulating blood cells caused by Id2 deletion would ameliorate Ang II-induced target-organ damage. METHODS AND RESULTS We used gene-deleted and transgenic mice. We conducted kidney and bone marrow transplants. In contrast to Ang II-infused Id2(+/-), Id2(-/-) mice infused with Ang II remained normotensive and failed to develop albuminuria or renal damage. Bone marrow transplant of Id2(+/-) bone marrow to Id2(-/-) mice did not restore the blunted blood pressure response to Ang II. Transplantation of Id2(-/-) kidneys to Id2(+/-) mice also could not prevent Ang II-induced hypertension and renal damage. We verified the Ang II resistance in Id2(-/-) mice in a model of local tissue Ang II production by crossing hypertensive mice transgenic for rat angiotensinogen with Id2(-/-) or Id2(+/-) mice. Angiotensinogen-transgenic Id2(+/-) mice developed hypertension, albuminuria, and renal injury, whereas angiotensinogen-transgenic Id2(-/-) mice did not. We also found that vascular smooth muscle cells from Id2(-/-) mice showed an antisenescence phenotype. CONCLUSIONS Our bone marrow and kidney transplant experiments suggest that alterations in circulating immune cells or Id2 in the kidney are not responsible for Ang II resistance. The present studies identify a previously undefined role for Id2 in the pathogenesis of Ang II-induced hypertension.
Collapse
Affiliation(s)
- Petra Gratze
- Medical Faculty of the Charité, Experimental and Clinical Research Center, Franz Volhard Clinic, Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Afkir S, Nguelefack TB, Aziz M, Zoheir J, Cuisinaud G, Bnouham M, Mekhfi H, Legssyer A, Lahlou S, Ziyyat A. Arbutus unedo prevents cardiovascular and morphological alterations in L-NAME-induced hypertensive rats Part I: cardiovascular and renal hemodynamic effects of Arbutus unedo in L-NAME-induced hypertensive rats. JOURNAL OF ETHNOPHARMACOLOGY 2008; 116:288-295. [PMID: 18191352 DOI: 10.1016/j.jep.2007.11.029] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/16/2007] [Revised: 11/14/2007] [Accepted: 11/20/2007] [Indexed: 05/25/2023]
Abstract
Hypertension induced by nitric oxide synthase inhibition is associated with functional abnormalities of the heart and kidney. The aim of the present study was to investigate whether chronic treatment with Arbutus unedo leaf (AuL) or root (AuR) aqueous extracts can prevent these alterations. Six groups of rats were used: control group received tap water; N(G)-nitro-l-arginine methyl-ester (L-NAME) group treated with L-NAME at 40 mg/kg/day; AuL and AuR groups received simultaneously L-NAME (40 mg/kg/day) and Au leaves or roots extract at the same concentration 250 mg/kg/day; l-arginine and enalapril groups received simultaneously L-NAME (40 mg/kg/day) and l-arginine at 50mg/kg/day or enalapril at 15 mg/kg/day. Treatment of rats during 4 weeks with L-NAME caused an increase of the systolic blood pressure (SBP) accompanied by a ventricular hypertrophy, an impairment of endothelium-dependent vasorelaxation, an increase of the cardiac baroreflex sensitivity and a decrease of water, sodium and potassium excretion. The co-administration of AuL or AuR extracts with L-NAME reduces the development of increased SBP, ameliorates the vascular reactivity as well as the baroreflex sensitivity and normalizes the renal function. AuR reduces the ventricular hypertrophy but AuL do not. Enalapril associated with L-NAME reverses the majority of alterations induced by L-NAME while l-arginine only lightly ameliorates the vascular reactivity. These results show that chronic treatment with Arbutus extract regress the development of hypertension and ameliorate cardiovascular and renal functions in NO deficient hypertension.
Collapse
Affiliation(s)
- Saida Afkir
- UFR Physiologie et Pharmacologie, Laboratoire de Physiologie et Ethnopharmacologie, Département de Biologie, Faculté des Sciences, Université Mohamed Premier, BP 717, Bd Mohamed VI, 60000 Oujda, Morocco
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Moustafa-Bayoumi M, Alhaj MA, El-Sayed O, Wisel S, Chotani MA, Abouelnaga ZA, Hassona MD, Rigatto K, Morris M, Nuovo G, Zweier JL, Goldschmidt-Clermont P, Hassanain H. Vascular Hypertrophy and Hypertension Caused by Transgenic Overexpression of Profilin 1. J Biol Chem 2007; 282:37632-9. [DOI: 10.1074/jbc.m703227200] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
19
|
Abstract
Vascular remodeling is the result of a close interplay of changes in vascular tone and structure. In this review, the role of angiotension-converting enzyme (ACE) and the impact of ACE inhibition on vascular remodeling processes during vascular injury and restenosis, hypertension, atherosclerosis, and aneurysm formation are discussed. The role of ACE and angiotensin II (Ang II) in neointimal thickening has been firmly established by animal studies and is mediated by Ang II type 1 (AT(1)) receptor signaling events via monocyte chemoattractant protein-1 and NAD(P)H oxidase. ACE and Ang II are involved in the remodeling of large and resistance arteries during hypertension; here, cell proliferation and matrix remodeling are also regulated by signaling events downstream of the AT(1) receptor. In atherosclerosis, Ang II is involved in the inflammatory and tissue response, mediated by various signaling pathways downstream of the AT(1) receptor. Although ACE inhibition has been shown to inhibit atherosclerotic processes in experimental animal models, results of large clinical trials with ACE inhibitors were not conclusive. Remodeling of vessel dimensions and structure during aneurysm formation is counteracted by ACE inhibition. Here, a direct effect of ACE inhibitors on matrix metalloproteinase activity has to be considered as part of the working mechanism. The role of ACE2 in vascular remodeling has yet to be established; however, ACE2 has been shown to be associated with vascular changes in hypertension and atherosclerosis.
Collapse
Affiliation(s)
- Sylvia Heeneman
- Department of Pathology, Maastricht University, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.
| | | | | |
Collapse
|
20
|
Pathophysiology of Hypertension. Hypertension 2007. [DOI: 10.1016/b978-1-4160-3053-9.50009-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register]
|
21
|
Affiliation(s)
- Wang Seong Ryu
- Department of Internal Medicine, College of Medicine, Chung-Ang University, Seoul, Korea
| | - Sang Wook Kim
- Department of Internal Medicine, College of Medicine, Chung-Ang University, Seoul, Korea
| | - Chee Jeong Kim
- Department of Internal Medicine, College of Medicine, Chung-Ang University, Seoul, Korea
| |
Collapse
|
22
|
Angiotensin-Converting Enzyme Inhibitors. Hypertension 2007. [DOI: 10.1016/b978-1-4160-3053-9.50026-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
23
|
López-Hernández FJ, López-Novoa JM. The lord of the ring: mandatory role of the kidney in drug therapy of hypertension. Pharmacol Ther 2005; 111:53-80. [PMID: 16154201 DOI: 10.1016/j.pharmthera.2005.08.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2005] [Accepted: 08/01/2005] [Indexed: 12/21/2022]
Abstract
Strong evidence supports the idea that total peripheral resistance (TPR) is increased in all forms of human and experimental hypertension. Although the etiological participation of TPR in the origin and long-term maintenance of hypertension has been extensively debated, it now seems clear that the renal, nonadaptive, infinite gain-working, pressure-sensitive natriuresis and diuresis is the main mechanism of blood pressure control in the long term. The tissue, cellular, biochemical, and genetic sensors and executors of this process have not been fully identified yet, but the role of the renal medulla has gained growing attention as the physiopathological scenario in which the key regulatory elements reside. Specifically, the functionality of the renomedullary vasculature seems to be highly responsible for blood pressure control. The vasculature of the renal medulla becomes a new and more specific target for the therapeutic intervention of hypertension. Recent data on the effect of baroreceptor-controlled renal sympathetic activity on the long-term regulation of blood pressure are integrated. The renomedullary effects of the main antihypertensive drugs are discussed, and new perspectives for the therapeutic intervention of hypertension are outlined. Comparison of the genetic program of the renal medulla before and after the development of hypertension in spontaneously hypertensive and experimentally induced animal models might provide a mechanism for identifying the key genes that become activated or suppressed in the development of high blood pressure. These genes, their encoded proteins, or other elements related to their signalling and genetic pathways might serve as new and more specific targets for the pharmacological treatment of abnormally elevated blood pressure. Besides, proteins specifically located to the luminal side of the renomedullary vascular endothelium may serve as potential targets for site-directed drug and gene therapy.
Collapse
Affiliation(s)
- Francisco J López-Hernández
- Unidad de Investigación, Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain.
| | | |
Collapse
|
24
|
Schram MT, van Ittersum FJ, Spoelstra-de Man A, van Dijk RAJM, Schalkwijk CG, Ijzerman RG, Twisk JWR, Stehouwer CDA. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J Hum Hypertens 2005; 19:429-37. [PMID: 15647778 DOI: 10.1038/sj.jhh.1001812] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
We investigated the effects of aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril on urinary albumin excretion, endothelial function and inflammatory activity in hypertensive type II diabetic individuals. A total of 70 hypertensive type II diabetic individuals were treated with three antihypertensive strategies in a randomized, double-blind, double-dummy design. Blood pressure was titrated to levels below 130/85 mmHg or a decrease in systolic pressure of 10% with a diastolic pressure below 85 mmHg. After titration, patients were treated for 12 months. Mean blood pressures changed from 157/93, 151/94 and 149/93 at baseline to 135/80, 135/82 and 131/80 mmHg after titration in the hydrochlorothiazide (n=24), candesartan (n=24) and lisinopril (n=22) groups. About 70% reached target blood pressures. However, only 45% had blood pressures <130/85 mmHg. Urinary albumin excretion and levels of soluble vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 decreased (GEE regression coefficients, -2.40 mg/24 h (P<0.001), -85 ng/ml (P=0.01) and -50 ng/ml (P=0.02)), but brachial artery endothelium-dependent and -independent vasodilation and levels of von Willebrand factor and C-reactive protein did not change (GEE regression coefficients, 0.21 mm (P=0.07), 0.04 mm (P=0.43), 0.04 IU/ml (P=0.33) and -1.15 mg/l (P=0.64)). No differences in outcome variables between treatment groups were observed. These data show that achievement of target blood pressures below 130/85 mmHg in hypertensive type II diabetes is difficult. Aggressive antihypertensive therapy can improve urinary albumin excretion, endothelial function and inflammatory activity in hypertensive type II diabetic individuals, regardless of the type of antihypertensive therapy used.
Collapse
Affiliation(s)
- M T Schram
- Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
25
|
|
26
|
Abstract
BACKGROUND Vascular damage caused by cerebral ischemia leads to edema, hemorrhage formation, and worsened outcomes in ischemic stroke patients. Therapeutic interventions need to be developed to provide vascular protection. The purpose of this review is to identify the pathophysiologic processes involved in vascular damage after ischemia, which may lead to strategies to provide vascular protection in ischemic stroke patients. SUMMARY OF COMMENT The pathologic processes caused by vascular injury after an occlusion of a cerebral artery can be separated into acute (hours), subacute (hours to days), and chronic (days to months). Targets for intervention can be identified for all 3 stages. Acutely, superoxide is the predominant mediator, followed by inflammatory mediators and proteases subacutely. In the chronic phase, proapoptotic gene products have been implicated. CONCLUSIONS Pharmacological agents designed to target specific pathologic and protective processes affecting the vasculature should be used in clinical trials of vascular protection after acute ischemic stroke.
Collapse
Affiliation(s)
- Susan C Fagan
- Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Athens, Ga 30912-2450, USA.
| | | | | | | | | |
Collapse
|
27
|
Pereira LMM, Bezerra DG, Mandarim-de-Lacerda CA. Aortic wall remodeling in rats with nitric oxide deficiency treated by enalapril or verapamil. Pathol Res Pract 2004; 200:211-7. [PMID: 15200273 DOI: 10.1016/j.prp.2003.12.008] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Twenty mature male Wistar rats were maintained alive for 40 days, separated in four groups of five rats each: control, L-NAME (LN), L-NAME + Enalapril (LN + E), L-NAME + Verapamil (LN + V). Blood pressure (BP), left ventricular (LV) mass index, and aortic wall parameters were analyzed: aortic wall thickness, tunica media sectional area, surface density of lamellae (Sv[lamellae]), and smooth muscle cell nuclear profiles per section (SMC). At the end of the experiment, the LN group showed high BP and a high LV mass index (cardiac hypertrophy). The control group and the other groups showed significant differences in aortic wall thickness, tunica media sectional area, Sv[lamellae], and SMC. When comparing the LN group with both the LN + E group and the LN + V group, aortic thickness was not different. Tunica media sectional area and SMC differed between the LN group and the LN + E group. There were also differences between the LN group and the LN + V group in SMC. The Sv[lamellae] decreased in the following sequence: control group > LN group = LN + E group > LN + V group. In conclusion, treatment with enalapril and verapamil shows partial efficiency in preventing or treating aortic wall tunica media hypertrophy, suggesting that these alterations are due to a mechanism other than blood pressure control, where nitric oxide synthesis inhibition could be involved.
Collapse
MESH Headings
- Angiotensin-Converting Enzyme Inhibitors/pharmacology
- Animals
- Aorta, Thoracic/drug effects
- Aorta, Thoracic/pathology
- Blood Pressure/drug effects
- Calcium Channel Blockers/pharmacology
- Disease Models, Animal
- Drug Therapy, Combination
- Enalapril/pharmacology
- Heart Ventricles/drug effects
- Heart Ventricles/pathology
- Male
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/metabolism
- Muscle, Smooth, Vascular/pathology
- NG-Nitroarginine Methyl Ester/pharmacology
- Nitric Oxide/deficiency
- Rats
- Rats, Wistar
- Verapamil/pharmacology
Collapse
Affiliation(s)
- Leila M M Pereira
- Laboratório de Morfometria & Morfologia Cardiovascular, Universidade do Estado do Rio de Janeiro, Centro Biomédico, Av 28 de Setembro, 87 fds. CEP:20551-030, Rio de Janeiro, RJ, Brazil.
| | | | | |
Collapse
|
28
|
Abstract
Angiotensin II not only is a vasoconstrictor, but it also affects cell growth and apoptosis, inflammation, fibrosis, and coagulation. Blockade of the renin-angiotensin system, either with inhibitors of the generation of angiotensin (angiotensin-converting enzyme [ACE] inhibitors) or with blockers of angiotensin receptors, reduces blood pressure and inhibits other pathophysiological actions. These other effects provide benefits in coronary heart disease, heart failure, diabetic nephropathy, and stroke beyond blood pressure reduction. These benefits were first demonstrated with ACE inhibitors. However, the mechanism of action of angiotensin receptor blockers, which block angiotensin II stimulation at the angiotensin type 1 receptor but not at the type 2 receptor, may have advantages, particularly for endothelial dysfunction and vascular remodeling, as well as cardiac and renal protection. Recent multicenter trials suggest that ACE inhibitors and angiotensin receptor blockers may reduce morbidity and mortality associated with cardiovascular and renal disease beyond blood pressure reduction. Several studies with different angiotensin receptor blockers, including comparisons with ACE inhibitors, are under way, and should provide further guidance for their clinical use.
Collapse
Affiliation(s)
- Ernesto L Schiffrin
- Canadian Institutes of Health Research Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Montreal, Québec, Canada.
| |
Collapse
|